Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study

PURPOSE: Although programmed cell death 1 (PD-1) or programmed cell death ligand 1 (PD-L1) inhibitors have shown survival benefits in patients with non–small cell lung cancer (NSCLC), most patients progress. This study evaluated whether continuing pembrolizumab with additional chemotherapy after fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hyun Ae, Park, Sehhoon, Choi, Yoon-La, Lee, Se-Hoon, Ahn, Jin Seok, Ahn, Myung-Ju, Sun, Jong-Mu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359724/
https://www.ncbi.nlm.nih.gov/pubmed/35101883
http://dx.doi.org/10.1158/1078-0432.CCR-21-3646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9359724/
https://www.ncbi.nlm.nih.gov/pubmed/35101883
http://dx.doi.org/10.1158/1078-0432.CCR-21-3646

Ejemplares similares